- Home
- Companies
- north america
- for cancer therapy
Refine by
For Cancer Therapy Suppliers In North America
22 companies found
Technologybased inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing ...
Technologybased inLouvain-La-Neuve, BELGIUM
At IBA we dare to develop innovative solutions pushing back the limits of technology. We share ideas and know-how with our customers and our partners to bring new solutions for the diagnosis and treatment of cancer. We care about the well-being of ...
Proteus® has been inspired by everyday clinical practice. Through day-to-day interactions with the community, IBA is perfectly positioned to understand, and invest in, the user’s needs. These investments are directly translated into ...
Technologybased inBoca Raton, FLORIDA (USA)
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions. The recently introduced Sculptura robotic ...
By delivering a precise, calibrated dose of Superficial Radiation Therapy that only goes skin deep, patients can be safely treated right in their physician’s office. Each treatment is virtually painless. Low-dose Superficial ...
Technologybased inSacramento, CALIFORNIA (USA)
We are a next-generation biotechnology company creating an AI-powered platform for custom protein design. Our platform develops Novobinders: proprietary protein binders with diagnostic and therapeutic applications. AINovo Biotech works with select ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
Emerging from the Company’s proprietary ATAK™ CAR receptor library, Myeloid’s novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this ...
Technologybased inPoway, CALIFORNIA (USA)
VetStem Biopharma has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, VetStem pioneered the use ...
Technologybased inWoburn, MASSACHUSETTS (USA)
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and ...
Prostate cancer is the most prevalent cancer among men, and it is the second leading cause of cancer death among men in the United States. More than 500,000 cases are diagnosed annually. In the U.S. this year, 1 in 6 males will develop the disease ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, ...
Technologybased inBerkeley, CALIFORNIA (USA)
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell ...
CAR-T cell therapies are a class of treatments in which T cells are modified to express chimeric antigen receptors (CARs). CARs are engineered molecules that, when present on the surface of a T cell, enable a T cell to recognize a ...
Technologybased inParamus, NEW JERSEY (USA)
Starton is an emerging clinical-stage biotechnology company transforming standard of care therapies with proprietary dermal delivery technology, so people with cancer can receive continuous treatment to live better, longer. Focused on continuous ...
STAR-OLZ is a 7-day transdermal patch in development as the first product indicated for PARP inhibitor (PARPi) induced nausea and vomiting (PIINV). PARP inhibitors are a rapidly growing class of cancer therapies ...
Technologybased inFort Collins, COLORADO (USA)
Symbios Technologies is a world-leading developer of dynamic aqueous plasma technology platforms for water treatment, specialty manufacturing, and biotherapeutic applications. The privately held company was founded in January 2008 and is ...
Technologybased inFriendswood, TEXAS (USA)
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and ...
Technologybased inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder ...
Technologybased inSeattle, WASHINGTON (USA)
AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged ...
AVM0703 Induces & Mobilizes Gamma Delta+ NKT-Cells. AVM0703 triggers the production and release of gamma delta+ Natural Killer T-cells (AVM-NKT). These supercharged immune cells have unique properties and appear rapidly in the blood following a ...
Technologybased inSTONY BROOK, NEW YORK (USA)
Alpha-1 Biologics was founded by Cynthia L. Bristow, PhD, in June, 2011 for the purpose of developing patented biotechnology related to the generation of immune cells from stem cells within the body to treat immunodeficiency with the following ...
Technologybased inWichita, KANSAS (USA)
Neotherma Oncology is led by experienced healthcare executives who are working toward the dream of more effective treatments for cancer. NeoTherma Oncology is developing a groundbreaking type of radio frequency (RF) thermal treatment for deep solid ...
Technologybased inKerrville, TEXAS (USA)
Vitanova Biomedical, Inc. (VNB) is a San Antonio, TX-based early stage biotechnology company developing patented (pending) technology licensed from the University of Texas at San Antonio. The company’s cancer treatment, Light-Activated Intracellular ...
Vitanova Biomedical’s Cancer Therapy Technology Platform is Called Light-Activated Intracellular Acidosis (LAIA). Vitanova Biomedical (VNB) has developed a proprietary energy-based technique to elicit ...
Technologybased inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
Technologybased inBellevue, WASHINGTON (USA)
TerraPower leads in advanced nuclear energy because it has spent the last decade investing in and developing groundbreaking technologies. TerraPower’s innovators create technologies to provide safe, affordable and abundant carbon-free energy. They ...
Technologybased inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as ...